Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05278195 | Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers(CHANCEsub) | unknown | — | 300 | Zhongda HospitalOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04825470 | Liver Transplantation for Unresectable GIST Liver Metastases(TRANSGIST) | unknown | N/A | 50 | Hospital Universitario Virgen de la ArrixacaOTHER |
| 1 |
| Mar 11, 2022 |
| clinicaltrials |
| NCT05270642 | Plan for Microwave Thermal Field | unknown | N/A | 5 | Chinese PLA General HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03322280 | TACE Combined With Iodine-125 Seeds Implantation for HCC | unknown | N/A | 270 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT05242237 | Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform | unknown | — | 300 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05242757 | Clinical Study of MAK Immune Cells in the Treatment of PHC | unknown | N/A | 12 | Zhongnan HospitalOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05240404 | Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma | unknown | Phase 2 | 116 | Xiangya Hospital of Central South UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05240690 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | unknown | Phase 1 | 27 | Zhou FuxiangOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02009176 | Laparoscope Anatomical and Aon-anatomical Hepatectomy | unknown | N/A | 110 | Shuguo Zheng, MDOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05118451 | A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLC | unknown | N/A | 420 | Zhujiang HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05233358 | HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure | unknown | N/A | 176 | The Central Hospital of Lishui CityOTHER | 0 | Feb 10, 2022 | clinicaltrials |
| NCT05213637 | Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 430 | Chinese PLA General HospitalOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 72 | National Taiwan University HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05113290 | Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | unknown | Phase 4 | 66 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05162898 | Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma. | unknown | N/A | 90 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 27, 2022 | clinicaltrials |
| NCT03067493 | RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial(RAMEC) | unknown | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05202015 | Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study(HepCaSt) | unknown | — | 150 | Charite University, Berlin, GermanyOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT02192671 | HR Versus RFA for HCC in Patients With PHT(HR-HCC/PHT) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT03973112 | A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 123 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT04981665 | A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04715321 | CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma | unknown | — | 120 | Sun Yat-sen UniversityOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05171309 | Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | unknown | Phase 2 | 35 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05166772 | Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 22, 2021 | clinicaltrials |
| NCT03731910 | Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE | unknown | N/A | 35 | Seoul National University HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05161143 | Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05154812 | Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio | unknown | Early Phase 1 | 108 | Beijing Ditan HospitalOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05152498 | Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC) | unknown | Early Phase 1 | 142 | Beijing Ditan HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03338647 | SBRT or TACE for Advanced HCC | unknown | Phase 3 | 180 | University of AarhusOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT05135364 | HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | unknown | Phase 2 | 48 | Yue HanOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05088733 | Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA) | unknown | Early Phase 1 | 120 | Beijing Ditan HospitalOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05125094 | Prognostic Performance of Preoperative and Follow by Gadoxetic Enhanced MRI in HCC Patients After TACE | unknown | — | 300 | Shanghai Zhongshan HospitalOTHER | 0 | Nov 18, 2021 | clinicaltrials |
| NCT04973098 | Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma | unknown | Phase 1 | 13 | Peking UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05105815 | Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma | unknown | Early Phase 1 | 23 | Huashan HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05088811 | The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma | unknown | — | 80 | Alexandria UniversityOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT03042520 | Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment(LONGHEAD) | unknown | — | 200 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 2 | Oct 12, 2021 | clinicaltrials |
| NCT04443049 | To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma. | unknown | N/A | 170 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04796025 | TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study(T-Double) | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT04490694 | TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05056337 | Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | unknown | Phase 3 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT03591705 | TACE-HAIC vs. HAIC for Potentially Resectable HCC | unknown | N/A | 240 | Sun Yat-sen UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04531228 | TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial(Thalen) | unknown | N/A | 60 | Yunfei YuanOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04814043 | PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial(PLATIC) | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05053386 | Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma | unknown | N/A | 186 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05042336 | The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC | unknown | Phase 1 / Phase 2 | 49 | Sichuan UniversityOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT04724226 | Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma(C-couple) | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 14, 2022source: clinicaltrials